Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00443924 | Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma | PHASE1 | COMPLETED | 56 | — | — | Mar 1, 2007 | Apr 1, 2009 | Jan 21, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | Arm 1 |
| 2 | EXPERIMENTAL | Arm 2 |
| 3 | EXPERIMENTAL | Arm 3 |
| 4 | EXPERIMENTAL | Arm 4 |
| 5 | EXPERIMENTAL | Arm 5 |
| Name | Type | Description |
|---|---|---|
| INS115644 Ophthalmic Solution | DRUG | One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days |
| Placebo | DRUG | One drop of placebo in each eye every 12 hours for three days |
Inclusion Criteria: * Have a diagnosis of bilateral ocular hypertension or early primary open angle glaucoma * Have best corrected visual acuity in both eyes of at least +0.5 or better * Have normal endothelial cell counts and morphology Exclusion Criteria: * Are diagnosed with closed angle glauc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Bimatoprost, AGN-193408 |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol , 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test - Bimatoprost 0.01%, Reference - LUMIGAN, Bimatoprost , 0.01%, LUMIGAN 0.01% |
| Glaukos Corp | GKOS | 1 | — | Travoprost |